Valesca Anshau, Scientific Director for North America for Biognosys
Title: Unveils Enhanced Plasma Proteomics for High-Throughput Biomarker Discovery
Abstract: Biognosys, a leader in the field of proteomics solutions for drug discovery and development, has reached a significant milestone with the unveiling of advancements in its plasma proteomics workflows on the esteemed TrueDiscovery® platform. These advancements incorporate a pioneering plasma enrichment technique, signaling a paradigm shift in deep proteome exploration characterized by exceptional data quality, reproducibility, and efficiency. The TrueDiscovery® platform now boasts a depth of up to 8,000 protein groups and greater in plasma or serum with the novel P2 plasma enrichment system. Additionally, the release introduces a new, profound high-throughput workflow capable of analyzing up to 7,000 protein groups in cohort analyses with a 17min analytical gradient, facilitating proteome profiling with unprecedented turnaround times in large-scale studies. We have exemplified that on a 4-cancer plasma study of 99 specimens, acquired in 2.5 days. The challenge was to find an optimal combination of chromatography and gradient time for deep coverage and high throughput. The deep proteome coverage enables comprehensive profiling of cytokines and tissue leakage proteins like E3-ligases, histone-deacetylases, or transcription factors. Biognosys remains at the forefront of proteomics research, equipping biopharma researchers with unparalleled capabilities to unravel the intricacies of the plasma proteome, thus fostering groundbreaking discoveries in drug development and clinical applications.
